Panacea Biotech is trading lower by 3.2% at Rs 175 after the World Health Organisation (WHO) delisted its DTP-based combination and monovalent hepatitis B vaccines from its list of pre-qualified vaccines.
The company, in a filing to the BSE, said that its diphtheria-pertussis-tetanus based combination vaccine Easyfive, Ecovac4 and EnivacHB have been delisted by WHO from the list of pre-qualified drugs. However, WHO stated there is no evidence of quality or safety defects regarding these vaccines.
The stock opened at Rs 176 and touched a high of Rs 183 in intra-day deals. As many as 15,800 shares have changed hands till 1050 hours.
